P326 IS CARTILAGE THINNING DURING OSTEOARTHRITIS FOCAL OR GLOBAL?  by Dam, E.B. et al.
S176 Poster Presentations
gm/cm3 sd: 42.5, p = 0.01), but not with cortical density at the
14% site (1080.6 gm/cm3 sd: 52.3 vs 1069.8 gm/cm3 sd: 52.4,
p = 0.08) and 38% site (1150.3 gm/cm3 sd: 30.6 vs 1148.2
gm/cm3 sd: 33.8, p = 0.60). Tibia polar strength strain index
was also increased significantly at the 14% site (1739.05 sd:
445.1 vs 1607.41 sd: 410.47, p=0.007) and 38% site (1872.57
sd: 4790.34 vs 1716.34 sd: 428.934, p=0.002).
Tibio-femoral osteophytosis was associated with a significant
increase in total and trabecular BMD at the 4% site but not in
cortical BMD at 14% and 38% sites (see table). Joint space
narrowing displayed a weaker association with trabecular bone
density and and no significant association with cortical bone
density. Multivariate analyses of PQCT values adjusted to BMI,
gender and age were performed and did not significantly alter
the results
Conclusions: Radiographic osteoarthritis is associated with an
increase in volumetric BMD assessed by PQCT. However, this
increase is confined predominantly to trabecular bone rather
than cortical bone. This association is driven predominently by
the presence of osteophytes rather than joint space narrowing.
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SUSTAINED PATIENT ACCEPTABLE SYMPTOM STATE
(PASS), A CLINICALLY MEANINGFUL RESPONSE, WITH
LUMIRACOXIB: A POOLED ANALYSIS OF TWO
RANDOMIZED STUDIES IN PATIENTS WITH
OSTEOARTHRITIS
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1Service de Rhumatologie B, Hopital Cochin, Paris, France,
2Novartis Pharma AG, Basel, Switzerland
Purpose: It is unclear whether changes in measures of self-
reported pain used in clinical trials, such as the visual analogue
scale (VAS), are clinically relevant to patients. The Patient Ac-
ceptable Symptom State (PASS) was developed to assess a
meaningful clinical response from the patient’s perspective. A
set of symptom threshold scores has been proposed to indicate
when patients consider themselves to be well and satisfied with
treatment. The treatment of osteoarthritis (OA) pain and dis-
ease activity with lumiracoxib, celecoxib and placebo in terms of
sustained acceptable symptom state using the PASS criteria is
assessed here.
Methods: Data from two 13-week, international, multicentre,
randomized, double-blind, double-dummy, placebo-controlled,
parallel-group studies were pooled and analysed. The studies
included patients aged ≥18 years with symptomatic knee OA
(American College of Rheumatology criteria), OA pain intensity
in the target knee (≥40 mm on a 100 mm VAS), and requiring
analgesic therapy for ≥3 months. Patients were randomized to
receive lumiracoxib 100 mg once daily (od), lumiracoxib 100 mg
od following an initial dose of lumiracoxib 200 mg od for the first
2 weeks (100 mg od + initial dose), celecoxib 200 mg od or
placebo for 13 weeks. OA pain intensity in the target knee, pa-
tient’s global assessment of disease activity, both 100 mm VAS,
and the WOMAC™ LK 3.1 Function (difficulty in performing daily
activities) sub-scale score were assessed. The PASS thresholds
were defined as ≤32.3 mm (VAS) for OA pain intensity, ≤32.0 mm
(VAS) for the patient’s global assessment of disease activity and
P325 – Table 1. K-M estimates of the % of patients achieving treatment satisfaction, according to PASS criteria#
Lumiracoxib100 mg od Lumiracoxib100 mg od + initial dose Celecoxib200 mg od Placebo
(n=811) (n=805) (n=813) (n=806)
OA Pain intensity (K-M %) 32.88** 33.87*** 33.06** 26.61
Patient’s global assessment (K-M %) 31.55*** 30.04*** 29.71*** 21.99
WOMACTM Function score (K-M %) 31.86*** 31.70*** 29.61*** 22.08
#Sustained until the end of the 13-week treatment phase. **p<0.01; ***p<0.001 versus placebo, Wilcoxon test
≤21.08 (converted from VAS to Likert scale) for the WOMAC™
Function score. The time taken to achieve and maintain an ac-
ceptable symptom state (PASS) for all subsequent consecutive
visits until the end of the study was determined for each variable.
Kaplan-Meier (K-M) probabilities of achieving a PASS sustained
until the end of the 13-week treatment phase were estimated. K-
M probabilities were calculated up to the penultimate study visit
(scheduled at 8 weeks [Day 73]) because achievement of PASS
after this visit would be insufficient to demonstrate a sustained
effect. Pairwise treatment comparisons of K-M estimates were
evaluated using Wilcoxon tests.
Results: For OA pain intensity, patient’s global assessment of
disease activity, and the WOMAC™ Function sub-scale score, the
probability of achieving an acceptable symptom state, according
to the PASS criteria, sustained until the end of the 13-week
treatment phase, was significantly greater for lumiracoxib 100 mg
od (with or without initial dose) than for placebo. This was true
also for celecoxib 200 mg od. There was no significant difference
between celecoxib 200 mg od and either of the lumiracoxib
regimens for the achievement of sustained acceptable symptom
state for the three PASS criteria.
Conclusions: In terms of PASS criteria for OA pain intensity,
patients’ global assessment of disease activity, and WOMAC
function, treatment satisfaction sustained until the end of 13
weeks of treatment in OA patients is significantly more likely with
100 mg od lumiracoxib than with placebo. Lumiracoxib 100 mg
od and celecoxib 200 mg od showed similar efficacy, that was
considered clinically relevant to the patients, as assessed by
PASS.
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Purpose: During knee osteoarthritis (OA) several processes
influence the progression. Histology suggests that cartilage le-
sions cause focal thinning and denudation whereas generalized
OA causes gradual, global thinning. In this longitudinal study, we
investigated which of these processes that is most prominent
and evaluated two alternative cartilage thinning measures that
are focused towards global and focal thinning, respectively, for
their ability to monitor OA progression as defined by the Kellgren
& Lawrence score (KL).
Methods: A randomized population was selected with even
distribution among male and female with ages from 21 to 81
(mean 56) and BMI from 20 to 38 (mean 27). Both left and right
knees and both healthy and knees with varying degree of OA
were used giving a total of 249 knees in the study.
The KL score was determined from digital x-rays acquired in a
weight bearing position with the knees slightly flexed and the feet
in a fixed rotation.
MR scans were acquired using a sagittal Turbo 3D T1 sequence
on a 0.18T Esaote C-Span scanner with near-isotropic voxels and
slice thickness of 0.8mm. X-rays and MR scans were acquired
at baseline and after 21 months.
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The thickness of the medial tibial cartilage compartment was
measured using a fully automatic framework based on super-
vised learning and a statistical shape model. The method re-
sults in a thickness map - including denuded regions that are
measured with zero thickness. Aiming for global thinning, we
calculated the mean thickness. Aiming for focal thinning with no
specific anatomical location we calculated the 10% quantile of
the thickness map (denoted thickness Q10). For baseline mea-
surements, the thickness was normalized by the width of the
medial tibial plateau.
We tested the thickness quantifications for the ability to separate
the group of healthy knees (defined by KL 0) from OA knees (KL
> 0) both at baseline and using the relative longitudinal change.
The tests were performed using an un-paired t-test.
Results: At baseline, both mean thickness and thickness Q10
were able to separate the groups of healthy and OA knees.
For mean thickness, healthy knees were significantly (p = 0.05)
thicker than OA knees, with averages of 2.24 mm and 2.19 mm,
respectively. For thickness Q10, the thin part of healthy knees
were significantly (p = 0.0005) thicker than OA, with averages of
1.72 mm and 1.61 mm, respectively (see Fig. 1).
Fig. 1. Thickness Q10 at baseline for levels of OA defined by KL. Knees with KL
3 and KL 4 are pooled since there was only a single KL 4.
Both measures could also separate the groups of healthy and OA
knees when using the relative longitudinal changes. For mean
thickness, the average thinning was 2.3% for healthy and 5.9%
for OA knees. For Q10, this was 0.0% and 5.4%. Here, the two
p values were 0.005 and 0.009.
Conclusions: For both thickness measures, the longitudinal
cartilage thinning was significantly worse for knees with OA at
baseline. This suggests that both thickness quantifications are
suitable for use in longitudinal clinical trials.
The thickness Q10 measure was designed to pick up focal thin-
ning caused by lesions. The results show that the Q10 measure
is much better able to separate healthy from OA compared to
mean thickness at baseline. Also, the results suggest that the
opposite is the case for the longitudinal change.
We therefore propose that for diagnostic purposes, the Q10
measure is well suited for quantifying a life-time of lesions caused
by minor knee injuries - whereas for a clinical trial, with a relative
short study period where few extra focal lesions occur, mean
thickness quantification may be equally appropriate.
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RADIOGRAPHIC FINDINGS AND PHYSICAL
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Purpose: To evaluate the relationship of health-related quality
of life measures in subjects with knee osteoarthritis (OA) with
subjects’ physical characteristics and radiographic features of
their knee OA.
Methods: The Mayo Clinic Exercise-OA cohort consists of 306
community-based volunteers enrolled in a randomized controlled
trial to determine the effects of exercise on knee OA. At baseline:
pain, function and general physical and mental health were as-
sessed with the Knee injury and Osteoarthritis Outcome Score
(KOOS), the SF-36 health status questionnaire, and visual ana-
log scale (VAS). Standard Buckland-Wright semiflexed weight-
bearing AP and lateral x-rays of both knees were taken and each
compartment was graded by Kellgren/Lawrence (K/L) score.
Results: Worsening K/L grade of knee OA, involvement of the
patellofemoral joint and increasing BMI were all significantly
associated with progressively lower KOOS scores and SF-36
physical function scores, but not with decreased SF-36 mental
health scores. Increasing radiographic grade also significantly
correlated with higher VAS pain scores. Among these, mean SF-
36 physical function scores were 7% lower in overweight subjects
(BMI 25-29.9) and 15% lower in obese subjects (BMI ≥ 30) as
compared to those with normal BMI (< 25). Mean KOOS knee-
symptom scores were 8% poorer in subjects with patellofemoral
involvement vs. without, and mean VAS pain scores were 25%
worse in higher grade radiographic OA (K/L 3 and 4) than in
lower grades (K/L 1 and 2). Mental health scores were essen-
tially unchanged across all radiographic grades, compartments
involved, and BMI categories.
Conclusions: Based on patient reported health-related quality
of life measures, we found radiographic severity of knee OA,
patellofemoral involvement and greater BMI to have a significant
impact on knee pain and symptoms, as well as overall phys-
ical function. Furthermore, it appears that worse OA features
correspond to more physical distress but not necessarily poorer
mental or emotional well-being.
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Purpose: Hand osteoarthritis (H0A) has a very unpredictable
evolution with respect to both symptoms and structural changes.
No clear correlation between symptoms and radiographic severity
has been established. We miss studies on this topic. Further-
more, many patients at end radiographic stages of HOA are
painless, indicating a high discordance between symptoms and
structural severity of the disease.
Objective: To study the cross-sectional and longitudinal prospec-
tive relationship between symptom and radiographic severity in
HOA.
Methods: Two readers scored separately 105 pairs of radio-
